FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068492012> ?p ?o ?g. }

• W2068492012 endingPage "2391" @default.
• W2068492012 startingPage "2382" @default.
• W2068492012 abstract "To determine the efficacy of a daily dose of 81 mg aspirin in primary thrombosis prevention in asymptomatic, persistently antiphospholipid antibody (aPL)-positive individuals (those with positive aPL but no vascular and/or pregnancy events).The Antiphospholipid Antibody Acetylsalicylic Acid (APLASA) study was a multicenter, randomized, double-blind, placebo-controlled clinical trial in which asymptomatic, persistently aPL-positive individuals were randomized to receive a daily dose of 81 mg of aspirin or placebo. In a separate observational and parallel study, asymptomatic, persistently aPL-positive individuals who were taking aspirin or declined randomization were followed up prospectively.In the APLASA study, 98 individuals were randomized to receive aspirin or placebo (mean +/- SD followup period 2.30 +/- 0.95 years), of whom 48 received aspirin and 50 received placebo. In the observational study, 74 nonrandomized individuals were followed up prospectively (mean +/- SD followup period 2.46 +/- 0.76 years); 61 received aspirin and 13 did not. In the APLASA study, the acute thrombosis incidence rates were 2.75 per 100 patient-years for aspirin-treated subjects and 0 per 100 patient-years for the placebo-treated subjects (hazard ratio 1.04, 95% confidence interval 0.69-1.56) (P = 0.83). Similarly, in the observational study, the acute thrombosis incidence rates were 2.70 per 100 patient-years for aspirin-treated subjects and 0 per 100 patient-years for those not treated with aspirin. All but 1 patient with thrombosis in either study had concomitant thrombosis risk factors and/or systemic autoimmune disease at the time of thrombosis.Our results suggest that asymptomatic, persistently aPL-positive individuals do not benefit from low-dose aspirin for primary thrombosis prophylaxis, have a low overall annual incidence rate of acute thrombosis, and develop vascular events when additional thrombosis risk factors are present." @default.
• W2068492012 created "2016-06-24" @default.
• W2068492012 creator A5019135832 @default.
• W2068492012 creator A5020895246 @default.
• W2068492012 creator A5031470088 @default.
• W2068492012 creator A5038324495 @default.
• W2068492012 creator A5065080959 @default.
• W2068492012 creator A5067312796 @default.
• W2068492012 creator A5068243428 @default.
• W2068492012 creator A5074421005 @default.
• W2068492012 creator A5081717855 @default.
• W2068492012 creator A5090023931 @default.
• W2068492012 date "2007-01-01" @default.
• W2068492012 modified "2023-10-03" @default.
• W2068492012 title "Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody–positive individuals" @default.
• W2068492012 cites W1068632 @default.
• W2068492012 cites W1488742384 @default.
• W2068492012 cites W1491481195 @default.
• W2068492012 cites W1975218766 @default.
• W2068492012 cites W1980784832 @default.
• W2068492012 cites W1980832330 @default.
• W2068492012 cites W198418484 @default.
• W2068492012 cites W1990240394 @default.
• W2068492012 cites W1991721757 @default.
• W2068492012 cites W2007997454 @default.
• W2068492012 cites W2023459425 @default.
• W2068492012 cites W2025039880 @default.
• W2068492012 cites W2034841577 @default.
• W2068492012 cites W2041297457 @default.
• W2068492012 cites W2044043417 @default.
• W2068492012 cites W2044856209 @default.
• W2068492012 cites W2046245551 @default.
• W2068492012 cites W2054330426 @default.
• W2068492012 cites W2062467631 @default.
• W2068492012 cites W2064072392 @default.
• W2068492012 cites W2087791517 @default.
• W2068492012 cites W2107891353 @default.
• W2068492012 cites W2111718702 @default.
• W2068492012 cites W2125189646 @default.
• W2068492012 cites W2132823760 @default.
• W2068492012 cites W2138597449 @default.
• W2068492012 cites W2138751326 @default.
• W2068492012 cites W2143321563 @default.
• W2068492012 cites W2146203649 @default.
• W2068492012 cites W2153551773 @default.
• W2068492012 cites W2163428021 @default.
• W2068492012 cites W2258503797 @default.
• W2068492012 cites W2327141264 @default.
• W2068492012 cites W4249374822 @default.
• W2068492012 cites W4296981399 @default.
• W2068492012 doi "https://doi.org/10.1002/art.22663" @default.
• W2068492012 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17599766" @default.
• W2068492012 hasPublicationYear "2007" @default.
• W2068492012 type Work @default.
• W2068492012 sameAs 2068492012 @default.
• W2068492012 citedByCount "359" @default.
• W2068492012 countsByYear W20684920122012 @default.
• W2068492012 countsByYear W20684920122013 @default.
• W2068492012 countsByYear W20684920122014 @default.
• W2068492012 countsByYear W20684920122015 @default.
• W2068492012 countsByYear W20684920122016 @default.
• W2068492012 countsByYear W20684920122017 @default.
• W2068492012 countsByYear W20684920122018 @default.
• W2068492012 countsByYear W20684920122019 @default.
• W2068492012 countsByYear W20684920122020 @default.
• W2068492012 countsByYear W20684920122021 @default.
• W2068492012 countsByYear W20684920122022 @default.
• W2068492012 countsByYear W20684920122023 @default.
• W2068492012 crossrefType "journal-article" @default.
• W2068492012 hasAuthorship W2068492012A5019135832 @default.
• W2068492012 hasAuthorship W2068492012A5020895246 @default.
• W2068492012 hasAuthorship W2068492012A5031470088 @default.
• W2068492012 hasAuthorship W2068492012A5038324495 @default.
• W2068492012 hasAuthorship W2068492012A5065080959 @default.
• W2068492012 hasAuthorship W2068492012A5067312796 @default.
• W2068492012 hasAuthorship W2068492012A5068243428 @default.
• W2068492012 hasAuthorship W2068492012A5074421005 @default.
• W2068492012 hasAuthorship W2068492012A5081717855 @default.
• W2068492012 hasAuthorship W2068492012A5090023931 @default.
• W2068492012 hasConcept C126322002 @default.
• W2068492012 hasConcept C141071460 @default.
• W2068492012 hasConcept C142724271 @default.
• W2068492012 hasConcept C168563851 @default.
• W2068492012 hasConcept C204243189 @default.
• W2068492012 hasConcept C204787440 @default.
• W2068492012 hasConcept C207103383 @default.
• W2068492012 hasConcept C27081682 @default.
• W2068492012 hasConcept C2776874634 @default.
• W2068492012 hasConcept C2777628954 @default.
• W2068492012 hasConcept C2777910003 @default.
• W2068492012 hasConcept C2780868729 @default.
• W2068492012 hasConcept C44249647 @default.
• W2068492012 hasConcept C71924100 @default.
• W2068492012 hasConceptScore W2068492012C126322002 @default.
• W2068492012 hasConceptScore W2068492012C141071460 @default.
• W2068492012 hasConceptScore W2068492012C142724271 @default.
• W2068492012 hasConceptScore W2068492012C168563851 @default.
• W2068492012 hasConceptScore W2068492012C204243189 @default.

• next